|
Basic Characteristics of Mutations
|
|
Mutation Site
|
M125K |
|
Mutation Site Sentence
|
Three mutations (M125K, G130R, and C138Y) were located in the “a” determinant of the S protein. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
S |
|
Standardized Encoding Gene
|
S
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Hepatitis B, Chronic
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
10762559
|
|
Title
|
Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
|
|
Author
|
Seigneres B,Pichoud C,Ahmed SS,Hantz O,Trepo C,Zoulim F
|
|
Journal
|
The Journal of infectious diseases
|
|
Journal Info
|
2000 Apr;181(4):1221-33
|
|
Abstract
|
Prolonged administration of nucleoside analogues for chronic hepatitis B may result in the emergence of hepatitis B viral polymerase mutants. To gain insight into the mechanism involved in the virus's resistance to famciclovir, the amino acid sequences of the terminal protein and reverse-transcriptase (RT) domains of the viral polymerase were determined during therapy among 28 patients. The antiviral response was independent of viral genotypes, and nonresponse to famciclovir was associated with a complex variability of the RT domain. No mutation in the YMDD motif was observed, whereas an L528M mutation was clearly selected by famciclovir treatment in 2 patients, as well as 14 novel mutations in 7 patients. Clone sequence analysis of the RT domains of patients undergoing retreatment with famciclovir and/or lamivudine showed the selection of a preexisting drug-resistant mutant in one case and indicated that sequential antiviral therapy may allow the rapid selection of resistant strains.
|
|
Sequence Data
|
-
|